UNSPSC 51152401: Acetaminophen/chlorzoxazone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class MS200. This VA Drug Class (MS200) classifies this compound as belonging to the group SKELETAL MUSCLE RELAXANTS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51152401 Acetaminophen/chlorzoxazone is a Commodity code that appears in state and local procurement records primarily for opioid-antagonist and drug-deactivation products rather than the acetaminophen or muscle-relaxant compounds the code name suggests. The mismatch between the code's nominal scope and recent solicitation activity indicates limited relevant purchasing under this specific taxonomy entry. Recent opportunities tagged to this code show state and local health agencies sourcing naloxone (an opioid overdose reversal medication) and safe drug deactivation systems to support community health and harm-reduction initiatives, not analgesic or muscle-relaxant pharmaceuticals. The issuing bodies include county health departments and state health and human services commissions pursuing these acquisitions through competitive bidding and information-gathering mechanisms.

Seminole County, Florida solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually via IFB 60459723LAS, with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford and electronic bid submission through the county's e-Procurement Portal; the contract carried a two-year initial term with one-year renewal option and included FEMA-potential funding with associated federal compliance requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The geographic activity spans Florida and Texas; the code shows sparse recent activity overall, and the mismatch between its nominal pharmaceutical scope and the overdose-response and pharmacy-benefit products actually being procured suggests this code may not reliably capture state and local purchasing in either category.